Figures & data
Table 1 Demographic and clinical characteristics of the study population at baseline
Figure 1 Patient disposition.
![Figure 1 Patient disposition.](/cms/asset/26b6e786-92ad-4b21-acb4-4a5a6b1b888f/dddt_a_12173076_f0001_b.jpg)
Figure 2 Axial pain (A), peripheral pain (B), fatigue (C), and morning stiffness (D) at baseline (T0) and different time points on low-dose MR prednisone in patients with active or low-active spondyloarthritis.
Abbreviations: T0, baseline evaluation; MR, modified-release; NRS, numerical rating scale.
![Figure 2 Axial pain (A), peripheral pain (B), fatigue (C), and morning stiffness (D) at baseline (T0) and different time points on low-dose MR prednisone in patients with active or low-active spondyloarthritis.](/cms/asset/bfdefbcf-d5ad-49f5-b1a8-21c8e0e13395/dddt_a_12173076_f0002_c.jpg)
Table 2 Absolute changes in important clinical and laboratory variables in patients with active SpA after 12 weeks of treatment with low-dose MR prednisone